BLATOPICALGEL
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
REGRANEX (becaplermin gel 0.01%) by Smith and Nephew. Approved for human platelet-derived growth factor [epc]. First approved in 1997.
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGRANEX (becaplermin) is a topical gel formulation containing recombinant human platelet-derived growth factor (PDGF) approved in December 1997 for the treatment of lower extremity diabetic neuropathic ulcers. The product works by promoting chemotactic recruitment and proliferation of cells involved in wound repair and enhancing granulation tissue formation, mimicking the biological activity of endogenous PDGF. REGRANEX is indicated as an adjunctive therapy and is not a substitute for standard wound care practices including sharp debridement, pressure relief, and infection control. It represents a biologic approach to chronic wound management in the diabetic patient population.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Human Platelet-derived Growth Factor
Indications (1)
Clinical Trials (1)
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Started Dec 2000
84 enrolled
Foot UlcerDiabetic FootSkin Ulcer+1 more
Why This Matters for Your Career
Worked on REGRANEX at Smith and Nephew? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.